VisionPoint Advisory Group’s Zevra Therapeutics ZVRA Stock Holding History

VisionPoint Advisory Group’s Portfolio ZVRA Stock Details ZVRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-1,730	Closed	-$8.48K	–	808
2024 Q2	$8.48K	Buy	1,730 +530	+44%	+$2.51K	﹤0.01%	507
2024 Q1	$6.96K	Sell	1,200 -5,660	-83%	-$34.8K	﹤0.01%	499
2023 Q4	$44.9K	Hold	6,860	–	–	0.02%	250
2023 Q3	$33.1K	Sell	6,860 -2,182	-24%	-$10.9K	0.01%	290
2023 Q2	$46.1K	Sell	9,042 -1,175	-12%	-$6.33K	0.02%	217
2023 Q1	$49.9K	Hold	10,217	–	–	0.02%	141
2022 Q4	$54.6K	Hold	10,217	–	–	0.02%	133
2022 Q3	$64K	Hold	10,217	–	–	0.03%	95
2022 Q2	$63K	Buy	+10,217	New	+$46.6K	0.02%	99

Other funds holding ZVRA

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACM

Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.87B AUM 46.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VisionPoint Advisory Group's ZVRA Position: Q3 2024 in Review

VisionPoint Advisory Group sold out of Zevra Therapeutics (ZVRA) in Q3 2024, closing a stake of 1,730 shares — an estimated $8.48K sold.

VisionPoint Advisory Group first reported a position in ZVRA in Q2 2022 and held it in 9 quarters. The position peaked at $64K in Q3 2022. 108 funds tracked by Wall St. Rank hold ZVRA as of Q3 2024.

VisionPoint Advisory Group reported no remaining Zevra Therapeutics position as of Q3 2024 after selling out during the quarter.
VisionPoint Advisory Group sold 1,730 Zevra Therapeutics shares in Q3 2024, an estimated $8.48K.
VisionPoint Advisory Group first reported a position in Zevra Therapeutics in Q2 2022 and held it in 9 quarters.
VisionPoint Advisory Group's Zevra Therapeutics position peaked at $64K in Q3 2022.
108 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q3 2024.

Based on VisionPoint Advisory Group's 13F filing for Q3 2024, filed 15 Oct 2024.